This week, AstraZeneca has made its third big deal with a big pharmaceutical corporation. The $700 million deal with Inovio involves a new cancer drug.
AstraZeneca aims to get sole rights over an immune boosting medicine bought from Inovio. According to The Market Business, the pharmaceutical company which designed the drug gets $27.5 million down payment from the $700 million total amount due.
The success of this new AstraZeneca deal depends on the efficiency of the INO-3112 drug that is claimed to eradicate HPV types 16 and 18. AstraZeneca's research team is studying this new drug along with analyzing other drug options for immune therapy. Up to date, the INO-3112 medicine has reached its first and second phases of clinical trials.
AstraZeneca has strong competition on the market. In order to keep ahead of its competitor, the company needs to continue to provide results. Despites the research efforts, the pharmaceutical industry still did not find a cure for the fatal malady. At the cancer metastasis stage it is unfortunately impossible to make a prediction.
For decades, experts tried multiple angles of approach in order to find a cure for cancer. Among them, the most used today are radiotherapy, chemotherapy, and surgery. To those are adding various alternative medicines. However the disease keeps on running rampant in our modern world full of cures and solutions for other diseases.
Previously, AstraZeneca has signed other deals that can also benefit cancer treatment. These drugs are trying to stop cancer in its tracks. Recently, in July, the company announced that the Federal Drug Administration has approved the IRESSA (gefitinib) tablets, as the first-line treatment of patients with metastatic non-small cell lung cancer.
Scientists and pharmaceutical researchers also hope to develop a future vaccine for cancer. Experts agree that cancer is a disease of civilization, same as appendicitis, obesity or depression. The only viable way to succeed in the goal to eradicate them all is to continue research.
